• Clinical science
  • Clinician

Giant cell arteritis (Temporal arteritis…)

Summary

Giant cell arteritis (GCA) is a type of autoimmune vasculitis that causes chronic inflammation of large and medium-sized arteries, in particular the carotid arteries, its major branches, and the aorta. It is most common in white women over the age of 50, and approximately 50% of patients also have polymyalgia rheumatica. Patients usually present with constitutional symptoms (e.g., fever, weight loss, night sweats, fatigue, and malaise), new-onset headache, a tender, hardened temporal artery, jaw claudication, or amaurosis fugax. Laboratory tests typically show signs of inflammation (e.g., elevated erythrocyte sedimentation rate and CRP), and temporal artery biopsy should be performed to confirm the diagnosis. The classic histopathological findings are mononuclear infiltration of the vessel wall and formation of giant cells. If GCA is suspected, prompt administration of glucocorticoids is essential to reduce the risk of permanent vision loss and cerebral ischemia.

Epidemiology

  • Sex: >
  • Peak incidence: 70–79 years; rarely seen in patients < 50 years
  • Most common among individuals of northern European descent

Women of advanced age are particularly prone to the disease!
References:[1][2]

Epidemiological data refers to the US, unless otherwise specified.

Etiology

References:[1][2]

Pathophysiology

Giant cell arteritis is thought to be due to a cell-mediated immune response to endothelial injury. However, the initiating factors are not fully understood.

  1. Inflammation
  2. Local vascular damage: macrophages produce metalloproteinases → destruction of vessel wall structures (e.g., internal elastic lamina)
  3. Concentric intimal hyperplasia: macrophages and giant cells produce PDGF and VEGF → stimulate intimal proliferation → reduced blood flow and ischemia

References:[1]

Clinical features

  • Constitutional symptoms
    • Fever, weight loss, night sweats
    • Symptoms of anemia: fatigue and malaise
  • Symptoms of arterial inflammation: extracranial branches of the common carotid, internal carotid, and external carotid arteries (the temporal artery is the most commonly affected vessel)
  • Vision loss
  • Diplopia
  • Symptoms of polymyalgia rheumatica (if both diseases are present)

About 50% of patients with giant cell arteritis also have polymyalgia rheumatica!

References:[1][2]

Diagnostics

References:[1][2][3][4][5]

Pathology

References:[1]

Differential diagnoses

References:[6][1][2]

The differential diagnoses listed here are not exhaustive.

Treatment

Immediate administration of high-dose glucocorticoids is crucial to prevent permanent vision loss in patients with giant cell arteritis!
References:[7][1][8][9]

Acute management checklist

Begin treatment as soon as temporal arteritis is suspected. Do not wait for a biopsy.

Complications

References:[7][9]

We list the most important complications. The selection is not exhaustive.

  • 1. Seetharaman M. Giant Cell Arteritis (Temporal Arteritis). In: Diamond HS. Giant Cell Arteritis (Temporal Arteritis). New York, NY: WebMD. http://emedicine.medscape.com/article/332483. Updated November 21, 2016. Accessed February 8, 2017.
  • 2. Docken WP, Rosenbaum JT. Clinical Manifestations of Giant Cell (Temporal) Arteritis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/clinical-manifestations-of-giant-cell-temporal-arteritis. Last updated November 28, 2016. Accessed February 8, 2017.
  • 3. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. url: http://www.rheumatology.org/Portals/0/Files/Giant%20Cell%20Arteritis_Excerpt.pdf Accessed February 8, 2017.
  • 4. Hunder GG. Diagnosis of giant cell (temporal) arteritis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/diagnosis-of-giant-cell-temporal-arteritis. Last updated October 7, 2014. Accessed February 8, 2017.
  • 5. Wallach JB. Interpretation of Diagnostic Tests. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
  • 6. Herold G. Internal Medicine. Cologne, Germany: Herold G; 2014.
  • 7. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill Education; 2015.
  • 8. Fraser JA, Weyand CM, Newman NJ, Biousse V. The treatment of giant cell arteritis. Rev Neurol Dis. 2008; 5(3): pp. 140–152. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3014829/.
  • 9. Hunder GG. Treatment of giant cell (temporal) arteritis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/treatment-of-giant-cell-temporal-arteritis. Last updated September 14, 2016. Accessed February 8, 2017.
  • 10. Weyand CM, Goronzy JJ. Giant-Cell Arteritis and Polymyalgia Rheumatica. N Engl J Med. 2014; 371(1): pp. 50–57. doi: 10.1056/nejmcp1214825.
  • 11. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. 2010; 49(8): pp. 1594–1597. doi: 10.1093/rheumatology/keq039a.
  • 12. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008; 372(9634): pp. 234–245. doi: 10.1016/s0140-6736(08)61077-6.
  • Evans J, Steel L, Borg F, Dasgupta B. Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. RMD Open. 2016; 2(1): p. e000137. doi: 10.1136/rmdopen-2015-000137.
  • Germano G, Muratore F, Cimino L, et al. Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study. Rheumatology. 2014; 54(3): pp. 400–404. doi: 10.1093/rheumatology/keu241.
  • Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 2010; 33(8): pp. 1122–1128. doi: 10.1002/art.1780330810.
  • Oh LJ, Wong E, Gill AJ, McCluskey P, Smith JEH. Value of temporal artery biopsy length in diagnosing giant cell arteritis. ANZ J Surg. 2016; 88(3): pp. 191–195. doi: 10.1111/ans.13822.
  • Vodopivec I, Rizzo JF. Ophthalmic manifestations of giant cell arteritis. Rheumatology. 2018; 57(suppl_2): pp. ii63–ii72. doi: 10.1093/rheumatology/kex428.
  • Poller DN. The importance of skip lesions in temporal arteritis. J Clin Pathol. 2000; 53(2): pp. 137–139. doi: 10.1136/jcp.53.2.137.
  • Bley TA, Wieben O, Uhl M, Thiel J, Schmidt D, Langer M. High-Resolution MRI in Giant Cell Arteritis: Imaging of the Wall of the Superficial Temporal Artery. AJR Am J Roentgenol. 2005; 184(1): pp. 283–287. doi: 10.2214/ajr.184.1.01840283.
  • Bardi M, Diamantopoulos AP. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice summary. Radiol Med (Torino). 2019; 124(10): pp. 965–972. doi: 10.1007/s11547-019-01058-0.
  • Khan A, Dasgupta B. Imaging in Giant Cell Arteritis. Curr Rheumatol Rep. 2015; 17(8). doi: 10.1007/s11926-015-0527-y.
  • Armagan B, Yildirim A, Onur M, et al. VALIDATION OF THE GIANT CELL ARTERITIS CLASSIFICATION CRITERIA IN TURKISH PATIENTS. Rheumatology. 2019; 58(Supplement_2). doi: 10.1093/rheumatology/kez058.034.
  • Schmidt WA. Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology. 2018; 57(suppl_2): pp. ii22–ii31. doi: 10.1093/rheumatology/kex461.
  • AbuRahma, A & Bergan, J. Noninvasive Cerebrovascular Diagnosis. Berlin: Springer Science & Business Media; 2010.
  • Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2019; 79(1): pp. 19–30. doi: 10.1136/annrheumdis-2019-215672.
  • Nesher G, Breuer GS. Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update. Rambam Maimonides Med J. 2016; 7(4): p. e0035. doi: 10.5041/rmmj.10262.
  • Thomas Ness, Thorsten A. Bley, Wolfgang A. Schmidt, Peter Lamprecht. The Diagnosis and Treatment of Giant Cell Arteritis. Dtsch Arztebl Int. 2013. doi: 10.3238/arztebl.2013.0376.
  • Ponte C, Rodrigues AF, O’Neill L, Luqmani RA. Giant cell arteritis: Current treatment and management. World J Clin Cases. 2015; 3(6): p. 484. doi: 10.12998/wjcc.v3.i6.484.
  • Sait MR, Lepore M, Kwasnicki R, et al. The 2016 revised ACR criteria for diagnosis of giant cell arteritis – Our case series: Can this avoid unnecessary temporal artery biopsies?. Int J Surg. 2017; 9: pp. 19–23. doi: 10.1016/j.ijso.2017.09.003.
  • Ferri FF. Ferri's Clinical Advisor 2015 E-Book. Elsevier Health Sciences; 2014.
  • Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia Rheumatica and Giant-Cell Arteritis. N Engl J Med. 2002; 347(4): pp. 261–271. doi: 10.1056/nejmra011913.
  • Ball GV, Bridges SL. Vasculitis, 2nd Edition. Oxford, United Kingdom: Oxford University Press; 2008: p. 215.
  • Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology. 2018; 57(suppl_2): pp. ii32–ii42. doi: 10.1093/rheumatology/kex424.
last updated 06/12/2020
{{uncollapseSections(['G40BkT', '840OOT', 'u40pOT', 'IZ1Y120', 'D401lT', 'C40qlT', 'x40ElT', 'B40zlT', 'y40dNT', 'a31QSg0', 'A40RNT'])}}